Video

Dr. Ivanick on Advances in Interventional Pulmonology

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Nathaniel Ivanick, MD, FCCP, assistant professor of oncology, thoracic surgeon, Roswell Park Comprehensive Cancer Center, discusses advancements in interventional pulmonology.

In the past several years, the field of interventional pulmonology has witnessed significant growth, Ivanick explains. Diagnostically, the development started with the integration of conventional bronchoscopy, which allowed for further examination of lesions. This was followed by radial endobronchial ultrasound-guided transbronchial cryobiopsy wherein the centers of peripheral lesions could be assessed, greatly increasing diagnostic accuracy for patients, Ivanick says.

Following these advancements was the integration of navigational bronchoscopy and robotic navigational bronchoscopy. These technologies allowed providers to adequately biopsy lesions that were previously too small or in peripheral areas to be tested, Ivanick says.

In addition to diagnostic advances, therapeutic development with microwave ablation and photodynamic therapy could emerge into mainstream clinical practice within the next 5 years, Ivanick concludes.

Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD